1. 1. Azimi F, Jafariyan M, Khatami S, Mortazavi Y, Azad M. Assessment of thiopurine-based drugs according to thiopurine-S-methyltransferase genotype in patients with acute lymphoblastic leukemia. Iran J Ped Hematol Oncol 2014; 4:32-8.
2. 2. Dean L, Kane M. Mercaptopurine Therapy and TPMT and NUDT15 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al (eds). Medical Genetics Summaries: Bethesda, National Center for Biotechnology Information (US), 2012.
3. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism;Szumlanski;DNA Cell Biol,1996
4. 4. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) en-coded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997; 10:94:6444-9.
5. 5. Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez-Alvarado M, Weinshilboum RM. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci U S A 2005; 28:102:9394-9.